Independent, Non-Executive Director
John Pavlidis joined the VHT board in February 2015 and now has more than 30 years of experience as a senior healthcare executive, CEO, or company director in the areas of women’s health, diagnostic imaging, image analysis and artificial intelligence, and cardiovascular therapies.
John is currently CEO of EosDx Inc. an early-stage start-up pioneering the accurate and non-invasive early detection of cancer. From 2015 through 2019, John served as the President and CEO of Vytronus, Inc., a venture-backed start-up using novel catheter-based ultrasound, machine learning and robotics technology to treat atrial fibrillation, a cardiac arrhythmia. Prior to Vytronus, John was the President and CEO of Endoscopic Technologies, Inc., a leader in minimally invasive and endoscopic treatment of atrial fibrillation, until it was acquired by AtriCure, Inc. in 2014. Since 2007, John has also served on the board of directors of several health technology companies, including U-systems, Inc., which pioneered automated breast ultrasound imaging as an adjunct to mammography for breast cancer screening and was acquired by GE Healthcare in 2012.
Previously, John served as President and CEO of R2 Technology, Inc., the pioneer and leader in computer-assisted detection of breast cancer, until Hologic, Inc. acquired the company in 2006. Before joining R2 Technology, John was president of the global Ultrasound business at Siemens Healthcare, where he led the acquisition and integration of Acuson and subsequent growth of the combined organization to $1 billion in revenue.
He is sharing his time between Europe and the USA.